247 related articles for article (PubMed ID: 20028747)
21. Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy.
Di Cosimo S
Breast Cancer Res; 2009; 11 Suppl 3(Suppl 3):S25. PubMed ID: 20030877
[No Abstract] [Full Text] [Related]
22. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis.
Lee HY; Oh SH; Woo JK; Kim WY; Van Pelt CS; Price RE; Cody D; Tran H; Pezzuto JM; Moriarty RM; Hong WK
J Natl Cancer Inst; 2005 Nov; 97(22):1695-9. PubMed ID: 16288123
[TBL] [Abstract][Full Text] [Related]
23. Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells.
Puli S; Jain A; Lai JC; Bhushan A
Neurochem Res; 2010 Jul; 35(7):986-93. PubMed ID: 20177775
[TBL] [Abstract][Full Text] [Related]
24. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
25. MTOR downregulates iodide uptake in thyrocytes.
de Souza EC; Padrón AS; Braga WM; de Andrade BM; Vaisman M; Nasciutti LE; Ferreira AC; de Carvalho DP
J Endocrinol; 2010 Jul; 206(1):113-20. PubMed ID: 20392814
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
Ghayad SE; Cohen PA
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
[TBL] [Abstract][Full Text] [Related]
27. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.
Peng DJ; Wang J; Zhou JY; Wu GS
Biochem Biophys Res Commun; 2010 Apr; 394(3):600-5. PubMed ID: 20214883
[TBL] [Abstract][Full Text] [Related]
28. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo.
West KA; Linnoila IR; Belinsky SA; Harris CC; Dennis PA
Cancer Res; 2004 Jan; 64(2):446-51. PubMed ID: 14744754
[TBL] [Abstract][Full Text] [Related]
29. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
[TBL] [Abstract][Full Text] [Related]
30. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression.
Hou L; Klann E
J Neurosci; 2004 Jul; 24(28):6352-61. PubMed ID: 15254091
[TBL] [Abstract][Full Text] [Related]
31. Luteinizing hormone stimulates mammalian target of rapamycin signaling in bovine luteal cells via pathways independent of AKT and mitogen-activated protein kinase: modulation of glycogen synthase kinase 3 and AMP-activated protein kinase.
Hou X; Arvisais EW; Davis JS
Endocrinology; 2010 Jun; 151(6):2846-57. PubMed ID: 20351317
[TBL] [Abstract][Full Text] [Related]
32. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway.
Lee KW; Yook JY; Son MY; Kim MJ; Koo DB; Han YM; Cho YS
Stem Cells Dev; 2010 Apr; 19(4):557-68. PubMed ID: 19642865
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells.
Xu Z; Zhang Y; Jiang J; Yang Y; Shi R; Hao B; Zhang Z; Huang Z; Kim JW; Zhang G
BMC Cancer; 2010 Apr; 10():161. PubMed ID: 20423485
[TBL] [Abstract][Full Text] [Related]
34. α-Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice.
Wang F; Ma H; Liu Z; Huang W; Xu X; Zhang X
Biomed Pharmacother; 2017 Aug; 92():672-680. PubMed ID: 28582759
[TBL] [Abstract][Full Text] [Related]
35. Delicaflavone induces autophagic cell death in lung cancer via Akt/mTOR/p70S6K signaling pathway.
Sui Y; Yao H; Li S; Jin L; Shi P; Li Z; Wang G; Lin S; Wu Y; Li Y; Huang L; Liu Q; Lin X
J Mol Med (Berl); 2017 Mar; 95(3):311-322. PubMed ID: 27838742
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
37. TIPE2 Induced the Proliferation, Survival, and Migration of Lung Cancer Cells Through Modulation of Akt/mTOR/NF-κB Signaling Cascade.
Bordoloi D; Banik K; Padmavathi G; Vikkurthi R; Harsha C; Roy NK; Singh AK; Monisha J; Wang H; Kumar AP; Kunnumakkara AB
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31817720
[TBL] [Abstract][Full Text] [Related]
38. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells.
West KA; Brognard J; Clark AS; Linnoila IR; Yang X; Swain SM; Harris C; Belinsky S; Dennis PA
J Clin Invest; 2003 Jan; 111(1):81-90. PubMed ID: 12511591
[TBL] [Abstract][Full Text] [Related]
39. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway.
Wang F; Mao Y; You Q; Hua D; Cai D
Int J Immunopathol Pharmacol; 2015 Sep; 28(3):362-73. PubMed ID: 26246196
[TBL] [Abstract][Full Text] [Related]
40. Gomisin N Exerts Anti-liver Cancer Effects and Regulates PI3K-Akt and mTOR-ULK1 Pathways in Vitro.
Zhu PL; Lam DF; Li JK; Fu XQ; Yin CL; Chou JY; Wang YP; Liu YX; Chen YJ; Wu JY; Wu Y; Bai JX; Liang C; Yu ZL
Biol Pharm Bull; 2020; 43(8):1267-1271. PubMed ID: 32741948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
